biotech
Snake Venom Toxin Inhibits Human Prostate Cancer Cell Growth
Filed in archive Drugs, Vaccines and Therapeutics by ruth on April 16, 2007
Snake Venom Toxin Inhibits Human Prostate Cancer Cell Growth
A study published in a recent issue of Molecular Cancer Therapeutics report on the effectiveness of the snake venom toxin (SVT) Vipera lebetina turanica in the inhibition of androgen-independent prostate cancer (AICAP).
The molecular focus of this report was on nuclear factor ΚB (NF- ΚB), an anti-apoptotic transcriptional factor that is constitutively activated in AICAP cell lines. The scientists showed that SVT inhibited growth of AICAP cells lines PC-3 and DU145 with IC50's of 1.7 and 1.8ug/mL, respectively. This exceeded the IC50 in LNCaP, androgen-sensitive cells (9.1ug/mL). With increasing concentrations of SVT, the number of cells distributed in the S phase of the cell cycle decreased significantly compare with cells in other phases.

According to the results of the study, a nanogram concentration range of SVT appears to inhibit the growth of AICAP through the NF-{kappa}B signal-mediated induction of cell death.

Photo: Macrovipera lebetina turanica, Wikipedia


Permalink: Snake Venom Toxin Inhibits Human Prostate Cancer Cell Growth
Tags: cancer  snake+venom  venom  prostate+cancer  apoptosis  biotech  venom+toxin 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/63902
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Snake Venom Toxin Inhibits Human Prostate Cancer Cell Growth:

  • Currently 9.47/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.47 out of 45 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!